129 related articles for article (PubMed ID: 38173291)
1. BRAF
Grillo F; Paudice M; Pigozzi S; Dono M; Lastraioli S; Lugaresi M; Bozzano S; Tognoni C; Ali M; Sciallero S; Puccini A; Fassan M; Mastracci L
Histopathology; 2024 Apr; 84(5):877-887. PubMed ID: 38173291
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
Kuan SF; Navina S; Cressman KL; Pai RK
Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
[TBL] [Abstract][Full Text] [Related]
6. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
[TBL] [Abstract][Full Text] [Related]
7. A practical screening strategy for Lynch syndrome and Lynch syndrome mimics in colorectal cancer.
Yao ZG; Lv BB; Jing HY; Su WJ; Li JM; Fan H; Zhao MQ; Qin YJ; Sun XC
J Cancer Res Ther; 2021 Jul; 17(3):790-796. PubMed ID: 34269315
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.
Jin M; Hampel H; Zhou X; Schunemann L; Yearsley M; Frankel WL
Am J Clin Pathol; 2013 Aug; 140(2):177-83. PubMed ID: 23897252
[TBL] [Abstract][Full Text] [Related]
11. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
Zhang X; Wang L; Wang J; Zhao H; Wu J; Liu S; Zhang L; Li Y; Xing X
Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
[TBL] [Abstract][Full Text] [Related]
13. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial.
Roth RM; Hampel H; Arnold CA; Yearsley MM; Marsh WL; Frankel WL
Am J Clin Pathol; 2015 Mar; 143(3):336-43. PubMed ID: 25696791
[TBL] [Abstract][Full Text] [Related]
14. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
15. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
16. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.
Jiang W; Cai MY; Li SY; Bei JX; Wang F; Hampel H; Ling YH; Frayling IM; Sinicrope FA; Rodriguez-Bigas MA; Dignam JJ; Kerr DJ; Rosell R; Mao M; Li JB; Guo YM; Wu XY; Kong LH; Tang JH; Wu XD; Li CF; Chen JR; Ou QJ; Ye MZ; Guo FM; Han P; Wang QW; Wan DS; Li L; Xu RH; Pan ZZ; Ding PR;
Int J Cancer; 2019 May; 144(9):2161-2168. PubMed ID: 30521064
[TBL] [Abstract][Full Text] [Related]
17. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
19. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
20. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
